Last reviewed · How we verify

Ixabepilone + Capecitabine — Competitive Intelligence Brief

Ixabepilone + Capecitabine (Ixabepilone + Capecitabine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Microtubule stabilizer + Antimetabolite. Area: Oncology.

phase 3 Microtubule stabilizer + Antimetabolite β-tubulin (ixabepilone); Thymidylate synthase (capecitabine/5-FU) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ixabepilone + Capecitabine (Ixabepilone + Capecitabine) — R-Pharm. Ixabepilone stabilizes microtubules to prevent cell division, while capecitabine is a prodrug that converts to fluorouracil to inhibit DNA synthesis, together providing synergistic cytotoxic activity against cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ixabepilone + Capecitabine TARGET Ixabepilone + Capecitabine R-Pharm phase 3 Microtubule stabilizer + Antimetabolite β-tubulin (ixabepilone); Thymidylate synthase (capecitabine/5-FU)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Microtubule stabilizer + Antimetabolite class)

  1. R-Pharm · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ixabepilone + Capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/ixabepilone-capecitabine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: